Olympus America

Press Center

Olympus Previews AU3000i™ Immunoassay System


Chicago, IL, July 25, 2006 - As a follow-up to the announced July 2006 European entrance into the immunoassay market by Olympus Corporation (President: Tsuyoshi Kikukawa), Olympus America Inc. is previewing the highly anticipated AU3000i™ Immunoassay System to the U.S. market at the American Association for Clinical Chemistry's 2006 Annual Meeting and Clinical Lab Expo here.

The proven technologies and internal knowledge base associated with the company’s highly successful Olympus AU®-clinical chemistry systems serves as the strong foundation for the AU3000i Immunoassay System and its dedicated reagents.

The universal desire for enhanced quality of life in an aging society is central to the business direction for Olympus Corporation. This focus on healthcare and medical solutions has led to a steady increase in both sales and profits in the company’s medical and life science divisions. The 21st century is called “the era of life science,” and the Olympus Diagnostics business continues to actively invest in life science-related businesses and has achieved double-digit annual growth and global sales of approximately 45 billion yen.

Olympus first entered the diagnostics business in 1971. Since then, Olympus has expanded the business all over the world, focusing on clinical chemistry instrumentation, and started producing Olympus reagents in 1989. Currently, R&D and manufacturing sites are located in Japan, Germany, France and Ireland. This “system business” approach in which an instrument, reagents, maintenance and customer support can be provided together as one package, together with a “pay per reportable test” program, represents the Olympus customer-oriented response for high quality systems while understanding the worldwide necessity for cost constraint regarding capital equipment expenditures.

The global immunoassay market is estimated to be worth approximately $ 5.3 billion U.S. Dollars. Olympus enters with a system that, although new, is based on its established automation technology, system building competency, and extensive assay design and manufacturing experience. Following the European launch of the Olympus AU3000i Immunoassay System in July 2006, Olympus intends to bring the product to market in the U.S., Japan and other Asian markets once the regulatory requirements of each country are fulfilled.

The Olympus AU3000i Immunoassay System's entrance into the market will bring a new choice to laboratories. Key software operating steps are standardized between the Olympus AU-Chemistry and Olympus AU3000i analyzers, thereby allowing lab personnel to move easily between systems. Ease of use is enhanced by the Windows® operating system, touch screen interface, videos, color-coded graphics and integrated User's Guide. Other features include a throughput of 240 tests per hour, and random access processing.

The OLYMPUS SUPPORTVISION™ system, an Internet-based device management system for Olympus analyzers, allows real-time monitoring of instrument performance and proactive service intervention for enhanced customer support.

Currently, this system is being previewed in the U.S., and is for research use only, not for use in diagnostic procedures.

For more information about the Olympus AU3000i™ Immunoassay System in the U.S., contact Susan M. Watanabe, Ph.D., Senior Product Manager, Olympus Diagnostic Systems Group, Olympus America Inc. at (800) 223-0125, ext 105686, or at (484) 896-5686.

About Olympus Diagnostic Systems Group
Olympus Diagnostic Systems provides innovative solutions that meet the high productivity demands of hospitals, integrated healthcare delivery networks, reference labs, blood banks and pharmaceutical labs. Olympus offers the broadest standardized line of random access chemistry-immuno analyzers, along with lab automation systems, blood bank analyzers and reagents. Olympus solutions save laboratories time, maximize productivity, and deliver fast, reliable results.

About Olympus
Olympus is a precision technology leader, designing and delivering innovative solutions in healthcare and consumer electronics worldwide. Olympus works collaboratively with its customers and its parent company, Tokyo-based Olympus Corporation, to leverage R&D investment in precision technology and manufacturing processes across diverse business lines. These include:

•  Gastrointestinal endoscopes, accessories, and minimally invasive surgical products;

•  Advanced clinical and research microscopes;

•  Lab automation systems, chemistry-immuno and blood bank analyzers and reagents; and

•  Digital and film cameras, and digital voice recorders.

In the U. S. and Canada, Olympus serves healthcare, scientific and commercial laboratory markets with integrated product solutions and financial, educational and consulting services that help customers efficiently, reliably, safely, and easily achieve superior results. Olympus is the leader in gastrointestinal endoscopy and clinical and educational microscopes. The company's consumer electronics business spans North and South America. For more information, visit www.olympusamerica.com.